Xiaoping Wan

Data from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer

SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1–PD-L1 axis

An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer

Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer

miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint

Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study

Circadian rhythms govern cardiac repolarization and arrhythmogenesis